Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.30 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507295 | 0.88 | ACHE (0.53) | ACHEBACE1 | |
| SCHEMBL16469274 | 0.87 | ACHE (0.57) | ACHEBACE1ALDH1A1 | |
| SCHEMBL30011553 | 0.87 | ACHE (0.57) | ACHEBACE1ALDH1A1 | |
| SCHEMBL29717643 | 0.87 | ACHE (0.57) | ACHEBACE1ALDH1A1 | |
| SCHEMBL16489154 | 0.81 | ACHE (0.40) | ACHEBACE1MAOAALDH1A2ALDH1A1 | |
| SCHEMBL7581528 | 0.79 | ACHE (0.47) | ACHEBACE1 | |
| SCHEMBL29717549 | 0.72 | ACHE (0.45) | ACHEBACE1MAOAALDH1A1 | |
| SCHEMBL29587810 | 0.72 | ACHE (0.45) | ACHEBACE1MAOAALDH1A1 | |
| SCHEMBL4192027 | 0.71 | ACHE (0.44) | ACHEBACE1MAOA | |
| SCHEMBL29717630 | 0.71 | ACHE (1.00) | ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9668985-B2 | Pterosin derivative-containing therapeutic preparation for disease associated with cartilage loss, cartilage degeneration and/or cartilage thinning | KYOTO UNIVERSITY (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20150051293-A1 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING | KYOTO UNIVERSITY (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051293-A1 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING | SYVN1, ADAMTS5, ADAMTS1 | ACHE 4558/4885BACE1 4867/4885MAOA 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.